Neurocrine/$NBIX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Neurocrine
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
- Ticker
- $NBIX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- San Diego, United States
- Website
- www.neurocrine.com
Neurocrine Metrics
BasicAdvanced
$17B
24.45
$6.73
0.33
-
Price and volume
Market cap
$17B
Beta
0.33
52-week high
$186.12
52-week low
$122.14
Average daily volume
1.5M
Financial strength
Current ratio
2.04
Quick ratio
1.723
Long term debt to equity
0.101
Total debt to equity
0.116
Interest coverage (TTM)
307.97%
Profitability
EBITDA (TTM)
1,069.1
Gross margin (TTM)
64.67%
Net profit margin (TTM)
18.98%
Operating margin (TTM)
26.62%
Effective tax rate (TTM)
24.63%
Revenue per employee (TTM)
$1,480,000
Management effectiveness
Return on assets (TTM)
12.45%
Return on equity (TTM)
20.41%
Valuation
Price to earnings (TTM)
24.445
Price to revenue (TTM)
4.482
Price to book
4.3
Price to tangible book (TTM)
14.05
Price to free cash flow (TTM)
15.957
Free cash flow yield (TTM)
6.27%
Free cash flow per share (TTM)
10.317
Growth
Revenue change (TTM)
37.98%
Earnings per share change (TTM)
60.66%
3-year revenue growth (CAGR)
27.55%
10-year revenue growth (CAGR)
73.47%
3-year earnings per share growth (CAGR)
52.78%
10-year earnings per share growth (CAGR)
16.58%
What the Analysts think about Neurocrine
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Analyst projections of the future price of Neurocrine stock.
Bulls say / Bears say
Third-quarter revenue rose 41% to $1.1 billion, while adjusted diluted earnings per share grew to $3.29 from $2.17 a year earlier. Sales growth from three marketed medicines is giving Neurocrine greater scale and a broader base for growth. (PR Newswire)
INGREZZA sales rose 17% in the third quarter, with record prescriptions, and Neurocrine raised its 2026 sales guidance to $2.9–$2.925 billion. Management expects double-digit volume growth to outpace pricing pressure next year. (PR Newswire, The Motley Fool)
CRENESSITY sales more than doubled year on year to $211 million, yet the company says it has reached only over 15% of diagnosed US patients with classic CAH. Phase 3 readouts in depression and schizophrenia also offer further potential catalysts in 2027. (PR Newswire)
INGREZZA faces tougher pricing and competition: Neurocrine expects mid- to high-single-digit net price pressure in 2027, while rival Austedo is gaining sales and will have a lower Medicare negotiated price. If volume growth does not offset these pressures, the company’s largest product could lose momentum. (The Motley Fool, Yahoo Finance)
VYKAT XR’s growth may be delayed by post-marketing safety concerns, which Neurocrine says require close monitoring and attention to appropriate patient selection. That could weigh on uptake of a product expected to help broaden the company’s revenue base. (The Motley Fool)
The surge in sales has not yet lifted GAAP profit: third-quarter net income slipped to $207 million from $210 million a year earlier. The Soleno acquisition and higher research and commercial spending add execution costs, while cash and marketable securities stood at $790 million at quarter-end. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Neurocrine Financial Performance
Revenues and expenses
Neurocrine Earnings Performance
Company profitability
Upcoming events
No upcoming events
Neurocrine News
AllArticlesVideos
Funds containing Neurocrine
AllUSDEURGBP
Fund name | Fund size | $NBIX weighting |
|---|---|---|
iShares Healthcare Innovation€2B78 | $1.2B | 1.14% |
iShares Healthcare Innovation£DRDR | $1.3B | 1.14% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.14% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.07% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.